Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds

Jonathan J. Cherry, Erkan Y. Osman, Matthew C. Evans, Sungwoon Choi, Xuechao Xing, Gregory D. Cuny, Marcie A. Glicksman, Christian L. Lorson, Elliot Androphy

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes progressive muscle weakness, which primarily targets proximal muscles. About 95% of SMA cases are caused by the loss of both copies of the SMN1 gene. SMN2 is a nearly identical copy of SMN1, which expresses much less functional SMN protein. SMN2 is unable to fully compensate for the loss of SMN1 in motor neurons but does provide an excellent target for therapeutic intervention. Increased expression of functional full-length SMN protein from the endogenous SMN2 gene should lessen disease severity. We have developed and implemented a new high-throughput screening assay to identify small molecules that increase the expression of full-length SMN from a SMN2 reporter gene. Here, we characterize two novel compounds that increased SMN protein levels in both reporter cells and SMA fibroblasts and show that one increases lifespan, motor function, and SMN protein levels in a severe mouse model of SMA. Spinal muscular atrophy (SMA) is caused by loss of SMN and is one of the leading heritable causes of infant death. The Authors describe new small molecules that increase SMN levels leading to improved lifespan and motor function in a SMA mouse model.

Original languageEnglish
Pages (from-to)1035-1050
Number of pages16
JournalEMBO Molecular Medicine
Volume5
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Spinal Muscular Atrophy
Pharmaceutical Preparations
Proteins
High-Throughput Screening Assays
Muscle Weakness
Motor Neurons
Reporter Genes
Neurodegenerative Diseases
Genes
Cause of Death
Fibroblasts
Muscles

Keywords

  • Drug discovery
  • SMA
  • SMN
  • SMN2
  • Spinal muscular atrophy

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. / Cherry, Jonathan J.; Osman, Erkan Y.; Evans, Matthew C.; Choi, Sungwoon; Xing, Xuechao; Cuny, Gregory D.; Glicksman, Marcie A.; Lorson, Christian L.; Androphy, Elliot.

In: EMBO Molecular Medicine, Vol. 5, No. 7, 07.2013, p. 1035-1050.

Research output: Contribution to journalArticle

Cherry, JJ, Osman, EY, Evans, MC, Choi, S, Xing, X, Cuny, GD, Glicksman, MA, Lorson, CL & Androphy, E 2013, 'Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds', EMBO Molecular Medicine, vol. 5, no. 7, pp. 1035-1050. https://doi.org/10.1002/emmm.201202305
Cherry, Jonathan J. ; Osman, Erkan Y. ; Evans, Matthew C. ; Choi, Sungwoon ; Xing, Xuechao ; Cuny, Gregory D. ; Glicksman, Marcie A. ; Lorson, Christian L. ; Androphy, Elliot. / Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. In: EMBO Molecular Medicine. 2013 ; Vol. 5, No. 7. pp. 1035-1050.
@article{b82f8cb38f7e4561a818c152a6c1118e,
title = "Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds",
abstract = "Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes progressive muscle weakness, which primarily targets proximal muscles. About 95{\%} of SMA cases are caused by the loss of both copies of the SMN1 gene. SMN2 is a nearly identical copy of SMN1, which expresses much less functional SMN protein. SMN2 is unable to fully compensate for the loss of SMN1 in motor neurons but does provide an excellent target for therapeutic intervention. Increased expression of functional full-length SMN protein from the endogenous SMN2 gene should lessen disease severity. We have developed and implemented a new high-throughput screening assay to identify small molecules that increase the expression of full-length SMN from a SMN2 reporter gene. Here, we characterize two novel compounds that increased SMN protein levels in both reporter cells and SMA fibroblasts and show that one increases lifespan, motor function, and SMN protein levels in a severe mouse model of SMA. Spinal muscular atrophy (SMA) is caused by loss of SMN and is one of the leading heritable causes of infant death. The Authors describe new small molecules that increase SMN levels leading to improved lifespan and motor function in a SMA mouse model.",
keywords = "Drug discovery, SMA, SMN, SMN2, Spinal muscular atrophy",
author = "Cherry, {Jonathan J.} and Osman, {Erkan Y.} and Evans, {Matthew C.} and Sungwoon Choi and Xuechao Xing and Cuny, {Gregory D.} and Glicksman, {Marcie A.} and Lorson, {Christian L.} and Elliot Androphy",
year = "2013",
month = "7",
doi = "10.1002/emmm.201202305",
language = "English",
volume = "5",
pages = "1035--1050",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds

AU - Cherry, Jonathan J.

AU - Osman, Erkan Y.

AU - Evans, Matthew C.

AU - Choi, Sungwoon

AU - Xing, Xuechao

AU - Cuny, Gregory D.

AU - Glicksman, Marcie A.

AU - Lorson, Christian L.

AU - Androphy, Elliot

PY - 2013/7

Y1 - 2013/7

N2 - Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes progressive muscle weakness, which primarily targets proximal muscles. About 95% of SMA cases are caused by the loss of both copies of the SMN1 gene. SMN2 is a nearly identical copy of SMN1, which expresses much less functional SMN protein. SMN2 is unable to fully compensate for the loss of SMN1 in motor neurons but does provide an excellent target for therapeutic intervention. Increased expression of functional full-length SMN protein from the endogenous SMN2 gene should lessen disease severity. We have developed and implemented a new high-throughput screening assay to identify small molecules that increase the expression of full-length SMN from a SMN2 reporter gene. Here, we characterize two novel compounds that increased SMN protein levels in both reporter cells and SMA fibroblasts and show that one increases lifespan, motor function, and SMN protein levels in a severe mouse model of SMA. Spinal muscular atrophy (SMA) is caused by loss of SMN and is one of the leading heritable causes of infant death. The Authors describe new small molecules that increase SMN levels leading to improved lifespan and motor function in a SMA mouse model.

AB - Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes progressive muscle weakness, which primarily targets proximal muscles. About 95% of SMA cases are caused by the loss of both copies of the SMN1 gene. SMN2 is a nearly identical copy of SMN1, which expresses much less functional SMN protein. SMN2 is unable to fully compensate for the loss of SMN1 in motor neurons but does provide an excellent target for therapeutic intervention. Increased expression of functional full-length SMN protein from the endogenous SMN2 gene should lessen disease severity. We have developed and implemented a new high-throughput screening assay to identify small molecules that increase the expression of full-length SMN from a SMN2 reporter gene. Here, we characterize two novel compounds that increased SMN protein levels in both reporter cells and SMA fibroblasts and show that one increases lifespan, motor function, and SMN protein levels in a severe mouse model of SMA. Spinal muscular atrophy (SMA) is caused by loss of SMN and is one of the leading heritable causes of infant death. The Authors describe new small molecules that increase SMN levels leading to improved lifespan and motor function in a SMA mouse model.

KW - Drug discovery

KW - SMA

KW - SMN

KW - SMN2

KW - Spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=84880027680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880027680&partnerID=8YFLogxK

U2 - 10.1002/emmm.201202305

DO - 10.1002/emmm.201202305

M3 - Article

C2 - 23740718

AN - SCOPUS:84880027680

VL - 5

SP - 1035

EP - 1050

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 7

ER -